Astria Therapeutics, Inc.
ATXS
$4.04
$0.061.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.41% | -38.40% | -92.36% | -78.12% | -136.82% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.03% | 10.79% | 31.29% | 67.81% | 342.86% |
| Change in Net Operating Assets | 660.57% | -439.36% | 1,171.53% | 58.60% | -150.60% |
| Cash from Operations | 42.58% | -96.14% | -56.98% | -44.07% | -183.55% |
| Capital Expenditure | 100.00% | -400.00% | -- | -- | 48.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -85.85% | -- | -17.05% | -164.73% | 98.52% |
| Cash from Investing | -84.38% | 154,800.00% | -17.58% | -164.74% | 98.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 13,810.00% | -65.57% | 383,162.16% | -26.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 13,810.00% | -65.57% | 383,162.16% | -26.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.83% | 54.24% | -24.08% | -101.94% | 318.98% |